M353-0039
M353-0039 is a selective UT-A2 inhibitor with a human IC50 of 0.35 μM. M353-0039 blocks urea transport mediated by UT-A2. M353-0039 can be used for the study of hyponatremia and edema associated with congestive heart failure, nephrotic syndrome, and cirrhosis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1185074-29-6
- 分子式: C16H15N3O3S2
- 分子量:361.44
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
体外実験
M353-0039 (50 seconds) potently and selectively inhibits UT-A2 in human UT-A2-overexpressing HEK293F cells with an IC50 of 0.35 μM, showing no activity against UT-A3 or UT-B[1].
M353-0039 (10-100 μM; 30 minutes) does not inhibit rat UT-A1-mediated urea transport in stably expressing MDCK cells[1].
M353-0039 (10 nM-100 μM; 6 minutes) does not inhibit mouse UT-B-mediated urea transport in erythrocytes[1].
M353-0039 (10 μM; 5 minutes) inhibits urea transport in human HepG2 cells, confirming UT-A2-mediated urea efflux in these hepatic cells[1].
M353-0039 (50 μM) binds deeply to UT-A2, forming more interactions than prior inhibitors, including critical contacts in the unique "T-T" subpocket, which underpins its superior inhibitory potency[1].
M353-0039 (50 seconds) demonstrates that the C285 residue in UT-A2 is critical for its binding and inhibitory activity, as mutating it to alanine reduces potency and mutating it to tryptophan abolishes activity[1].
M353-0039 (100 μM; 24 hours) exhibits no cytotoxicity toward MDCK cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDCK cells
-
Concentration:100 μM
-
Incubation Time:24 hours
-
Result:Did not reduce MDCK cell viability compared to vehicle controls.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 8 weeks old)[1]
-
Dosage:80 mg/kg
-
Administration:i.p.; single dose
-
Result:Significantly reduced kidney medulla urea concentration (P=0.0186) and osmolarity (P=0.0037).
Significantly reduced urine urea concentration (P<0.0001) and osmolarity (P<0.0001).
Caused only a minor decrease in kidney medulla urea concentration (P=0.0310) in mice on normal diet plus water deprivation.
Produced no significant changes in urine urea concentration or osmolarity in mice on normal diet plus water deprivation.
化学情報
-
CAS 番号 1185074-29-6
-
分子量 361.44
-
分子式 C16H15N3O3S2
-
SMILES
CC1=CSC(C2=CC(NC(CNC(C3=CC=CO3)=O)=O)=C(S2)C)=N1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)